Biopharmaceutical company BerGenBio ASA (OSE:BGBIO) announced on Tuesday that the first patient has been enrolled in a clinical trial evaluating bemcentinib, its AXL kinase inhibitor, in combination with pacritinib, a JAK2 inhibitor.
The trial, sponsored by the Mays Cancer Center at UT Health San Antonio, will investigate this combination therapy in patients with lung adenocarcinoma.
Pacritinib is marketed in the United States as VONJO and is owned by biopharmaceutical company Swedish Orphan Biovitrum AB (Sobi) (STO:SOBI).
The study is funded by a grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH).
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
GSK agrees US pricing framework to expand access to respiratory medicines
Century Health partnerss with Tessel Biosciences to advance early drug development in COPD
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema
PureTech clears key FDA milestone for Phase 3 development of deupirfenidone
Orano Med and Roche advance pretargeted radioimmunotherapy into clinical phase
bioMérieux launches equine endocrinology tests to expand point-of-care diagnostics
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio